Brachyury

Preventing lung cancer's unwelcome return

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Cancer, Clinical medicine, Lung cancer, Oncology, Epidermal growth factor receptor, Oncogenes, Non-small-cell lung carcinoma, Brachyury, Neoplasm, KRAS, Somatic evolution in cancer

Cold Spring Harbor Laboratory (CSHL) Visiting Scientist Raffaella Sordella investigated a similar problem that occurs in some lung cancers .

Key Points: 
  • Cold Spring Harbor Laboratory (CSHL) Visiting Scientist Raffaella Sordella investigated a similar problem that occurs in some lung cancers .
  • Approximately 15% of non-small cell lung cancers have a mutation in a growth receptor called EGFR, causing tumor cells to grow uncontrollably.
  • Researchers developed an effective drug that inhibits EGFR and kills cancer cells, but the tumor grows back later.
  • Understanding how resistance arises in lung cancer is key to figuring out how to eliminate a tumor.

Worldwide Liver Cancer Hepatoma 2021 Industry Report - Identify Patient Segments Through Age Groups, Gender and Disease Sub-types - ResearchAndMarkets.com

Retrieved on: 
Friday, July 9, 2021
Health, Oncology, Hepatology, Medical specialties, Branches of biology, Clinical medicine, Cancer, Liver cancer, Liver, Brachyury

The "Global Liver Cancer Hepatoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Liver Cancer Hepatoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides Liver Cancer Hepatoma epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Liver Cancer Hepatoma patients, history of the disease at the population level (Liver Cancer Hepatoma prevalence, Liver Cancer Hepatoma incidence) and at the clinical level (from diagnosis to treated patients).
  • Liver Cancer Hepatoma patient flow: Liver Cancer Hepatoma prevalence, diagnosed, and drug-treated patients
    Demographics: Liver Cancer Hepatoma patients by age group, gender
    The data from this research will help executives:
    Establish basis for Liver Cancer Hepatoma market sizing, assessing market potential, and developing drug forecast models
    Identify Liver Cancer Hepatoma patients segments through age groups, gender, and disease sub-types
    Evaluate Liver Cancer Hepatoma market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005294/en/

OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

Retrieved on: 
Monday, June 7, 2021
Medical specialties, Hepatology, Clinical medicine, Branches of biology, Glypican 3, Brachyury, Orphan drugs, Hepatocellular carcinoma

Preliminary results from the study show promising safety and efficacy of Ori-CAR-001 in patients with GPC3-positive relapsed/refractory HCC.

Key Points: 
  • Preliminary results from the study show promising safety and efficacy of Ori-CAR-001 in patients with GPC3-positive relapsed/refractory HCC.
  • All subjects had advanced HCC and had failed prior lines of treatment including chemotherapy, TACE, and targeted therapies.
  • All subjects had BCLC stage C (late stage) HCC except for one subject with stage B (mid stage).
  • Among the 9 evaluable subjects, 4 achieved partial response (PR), 3 achieved stable disease (SD), and 2 had disease progression (PD).

Medivir announces the design of its upcoming MIV-818 combination study

Retrieved on: 
Tuesday, May 25, 2021
Medical specialties, Hepatology, Clinical medicine, Medicine, Medivir, Liver cancer, Cancer, Brachyury, Hepatocellular carcinoma, Bland embolization

It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer.

Key Points: 
  • It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer.
  • Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high.
  • There are 42,000 patients diagnosed with primary liver cancer per year in the US and current five-year survival is11 percent.
  • Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.

Topical MEK Inhibitor, NFX-179, Prevents Cutaneous Squamous Cell Carcinoma in Pre-Clinical Model

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Lung cancer, Neurofibroma, Organ systems, Brachyury, Anatomy, Infectious causes of cancer, Carcinoma, Squamous cell skin cancer

Near-complete suppression of cutaneous squamous cell carcinoma was observed only in the drug-treated area, demonstrating the targeted and local effect of the drug candidate.

Key Points: 
  • Near-complete suppression of cutaneous squamous cell carcinoma was observed only in the drug-treated area, demonstrating the targeted and local effect of the drug candidate.
  • "\nCutaneous squamous cell carcinoma is one of the most common cancers, with an estimated 700,000 cases diagnosed in the United States annually.
  • Risk factors for cutaneous squamous cell carcinoma include older age, male sex, fair pigmentation, ultraviolet exposure and immunosuppression.
  • NFlection is working to address RASopathies through the development of first-in-class soft MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments to mitigate or treat cutaneous neurofibromas in neurofibromatosis type 1, congenital birthmarks and immunosuppressant-mediated squamous cell carcinoma.

Novel late-stage colorectal cancer treatment proves effective in preclinical models

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Clinical medicine, Medicine, Exosome, Vesicles, Cancer, Colorectal cancer, Chemotherapy, Brachyury

b'MINNEAPOLIS/ST.PAUL, April 28, 2021 (GLOBE NEWSWIRE) -- In a recent discovery by University of Minnesota Medical School, researchers uncovered a new way to potentially target and treat late-stage colorectal cancer \xe2\x80\x93 a disease that kills more than 50,000 people each year in the United States.

Key Points: 
  • b'MINNEAPOLIS/ST.PAUL, April 28, 2021 (GLOBE NEWSWIRE) -- In a recent discovery by University of Minnesota Medical School, researchers uncovered a new way to potentially target and treat late-stage colorectal cancer \xe2\x80\x93 a disease that kills more than 50,000 people each year in the United States.
  • The team identified a novel mechanism by which colorectal cancer cells evade an anti-tumor immune response, which helped them develop an exosome-based therapeutic strategy to potentially treat the disease.\n\xe2\x80\x9cLate-stage colorectal cancer patients face enormous challenges with current treatment options.
  • Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine.
  • Visit med.umn.edu to learn how the University of Minnesota is innovating all aspects of medicine.\n'

Global Hepatocellular Carcinoma Market Report 2021: Opportunity Analysis and Forecasts 2019-2029 - Market Expected to Grow at 17.7% CAGR to $5.3 Billion - ResearchAndMarkets.com

Retrieved on: 
Monday, April 12, 2021
Health, Oncology, Medical specialties, Clinical medicine, Drugs, Hepatology, Orphan drugs, Hepatocellular carcinoma, Sorafenib, Brachyury, Cancer immunotherapy, Bevacizumab, Medivir

b'The "Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThe pipeline drugs in development for HCC are mostly already approved for other indications and HCC represents a growth strategy for the brands.\nThere are currently nine pipeline products in Phase III clinical trial; additionally, seven marketed agents are in clinical trials to expand their labels in new lines of therapy and new combinations within HCC.\nThe most common MOAs under investigation for HCC include tyrosine kinase inhibitors (TKI) and immuno-oncology (IO) agents (programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors).

Key Points: 
  • b'The "Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nThe pipeline drugs in development for HCC are mostly already approved for other indications and HCC represents a growth strategy for the brands.\nThere are currently nine pipeline products in Phase III clinical trial; additionally, seven marketed agents are in clinical trials to expand their labels in new lines of therapy and new combinations within HCC.\nThe most common MOAs under investigation for HCC include tyrosine kinase inhibitors (TKI) and immuno-oncology (IO) agents (programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors).
  • In addition to the active late-stage pipeline, there are a large number of ongoing Phase I and II trials.\nHepatocellular carcinoma (HCC) is the most frequent type of primary malignancy of the liver.
  • The prognosis of HCC is dependent on the stage of the disease at diagnosis.\nHowever, even with treatments such as surgical resection, liver transplantation, and ablative therapies, which are only suitable for early-stage HCC patients, the majority of patients are likely to progress onto the advanced stages of the disease.\nUntil the entry of Roche\'s combination therapy of Avastin + Tecentriq in May 2020, Bayer\'s multikinase inhibitor commanded the largest first-line and second-line patient share in the HCC market.\nThis led to a shift in multikinase inhibitor monotherapy as standard of care (SOC) and initiated a new strategy in the HCC market whereby combinations are now the predominant therapeutic option under development.\nUpon approval of Avastin + Tecentriq by the FDA, in May 2020, the combination replaced the SoC in first-line advanced HCC, shifting Nexavar and Lenvima to second-line treatment options.\nThe greatest drivers of growth in the global HCC market include the launch of new pipeline therapies, combinations of therapies with different MOAs, label expansion from other oncology indications to HCC, and label expansion into earlier lines of therapy, in addition to an increase in diagnosed incident cases in many 8MM countries.\nThe main barrier to growth in the HCC market is patent expiration of key biologic brands with subsequent biosimilar launch.\nThe most important unmet needs in the HCC market are better HCC surveillance and prophylactic treatments, curative therapies in early-stage HCC, improved survival for intermediate-stage HCC, data on sequencing of treatments, prognostic biomarkers, treatments for patients with impaired liver function.\n2.5 What Do Physicians Think?\n'

AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline

Retrieved on: 
Friday, March 26, 2021
Branches of biology, Alpha-synuclein, Lewy body dementia, Tau protein, Brachyury, Biology

During the webinar, members of the AC Immune Management and Research and Development Teams will discuss the unique benefits of the Companys innovative Morphomer technology platform, which accelerates the design, synthesis, and development of CNS-optimized, conformation-specific small molecules directed against pathological proteins.

Key Points: 
  • During the webinar, members of the AC Immune Management and Research and Development Teams will discuss the unique benefits of the Companys innovative Morphomer technology platform, which accelerates the design, synthesis, and development of CNS-optimized, conformation-specific small molecules directed against pathological proteins.
  • The platform has produced multiple clinically validated therapeutic and diagnostic candidates that bind selectively to target proteins intracellularly, at the earliest stages of disease.
  • The current Morphomer pipeline includes two clinical-stage diagnostic candidates (Tau-PET tracer and alpha-synuclein-PET tracer), and one therapeutic candidate that has completed Phase 1 (Morphomer Tau ACI-3024).
  • Following the formal presentations, there will be an interactive virtual roundtable discussion between the audience and the AC Immune Management and Research and Development Teams.

Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in Patients With Underlying Non-alcoholic Steatohepatitis (NASH)

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Hepatology, Clinical medicine, Medicine, Hepatocellular carcinoma, Liver cancer, Brachyury, Cancer, Ultrasonography of liver tumors, Transgene SA

The researchers led a large international collaboration to investigate immunotherapy's effect on hepatocellular carcinoma (HCC), a deadly liver cancer, caused by NASH.

Key Points: 
  • The researchers led a large international collaboration to investigate immunotherapy's effect on hepatocellular carcinoma (HCC), a deadly liver cancer, caused by NASH.
  • "These results also highlight the need for refined therapeutic strategies aimed at treating both the tumor as well as the microenvironment associated with distinct underlying liver disease."
  • While immunotherapy has clinical benefit for hepatocellular carcinoma, this study's findings are important because a quarter of all HCC patients have NASH.
  • The meta-analysis in this study was conducted on three high-quality phase 3 trials that included more than 1,600 HCC patients treated with anti-PD1 immunotherapy.

Global Hepatocellular Carcinoma (HCC) Market Analysis to 2038 - HCC Sales in the US, Japan, France, Germany, Italy, Spain, and UK to Rise to $2.5Bn by 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 9, 2021
Health, Oncology, Chemical compounds, Organic compounds, Hepatology, Branches of biology, Hepatocellular carcinoma, Transcription factors, Sorafenib, HCC, Brachyury

The "Hepatocellular carcinoma (HCC) Disease Coverage Forecast and Market Analysis to 2038" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepatocellular carcinoma (HCC) Disease Coverage Forecast and Market Analysis to 2038" report has been added to ResearchAndMarkets.com's offering.
  • Nexavar has been firmly established as the standard of care in advanced HCC since gaining approval in the US in 2007.
  • However, Nexavar is forecast to steadily lose market share after the introduction of generics in 2020 (US), 2021 (EU), and 2022 (Japan).
  • The publisher forecasts HCC sales in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) to rise from $681m in 2018 to $2.5bn in 2027.